ISO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IsoPlexis's book value per share for the quarter that ended in Dec. 2022 was $1.04.
During the past 12 months, IsoPlexis's average Book Value Per Share Growth Rate was -71.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
IsoPlexis's current price is $0.7616. Its book value per share for the quarter that ended in Dec. 2022 was $1.04. Hence, today's PB Ratio of IsoPlexis is 0.73.
During the past 4 years, the highest P/B Ratio of IsoPlexis was 2.85. The lowest was 0.64. And the median was 1.10.
The historical data trend for IsoPlexis's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Book Value per Share | -0.74 | -23.89 | 3.64 | 1.04 |
IsoPlexis Quarterly Data | |||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Book Value per Share | Get a 7-Day Free Trial | 3.64 | 2.94 | 2.30 | 1.86 | 1.04 |
For the Medical Devices subindustry, IsoPlexis's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's PB Ratio distribution charts can be found below:
* The bar in red indicates where IsoPlexis's PB Ratio falls into.
IsoPlexis's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (41.27 | - | 0.00) | / | 39.67 | |
= | 1.04 |
IsoPlexis's Book Value Per Share for the quarter that ended in Dec. 2022 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (41.27 | - | 0.00) | / | 39.67 | |
= | 1.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
IsoPlexis (NAS:ISO) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of IsoPlexis's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nachum Shamir | director | 12212 TECHNOLOGY BLVD, AUSTIN TX 78727 |
John Strahley | officer: Chief Financial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Sean Mackay | director, officer: Chief Executive Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rew Richard W. Ii | officer: SVP, GC & Secretary | 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735 |
James R Heath | director | C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405 |
Michael Egholm | director | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
Siddhartha Kadia | director | 7475 LUSK BOULEVARD, SAN DIEGO CA 92121 |
Jason W. Myers | director | C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301 |
John G. Conley | director | 396 GREAT MEADOWS RD, CONCORD MA 01742-1803 |
Gregory P. Ho | director, 10 percent owner | C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
Peter Siesel | officer: Chief Commercial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Jing Zhou | officer: Chief Scientific Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rajesh T. Khakhar | officer: VP, Finance | 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405 |
Northpond Capital Gp, Llc | 10 percent owner | 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 04-08-2022
By PurpleRose PurpleRose • 07-21-2022
By GlobeNewswire GlobeNewswire • 01-10-2022
By Business Wire Business Wire • 12-30-2022
By Value_Insider Value_Insider • 10-19-2022
By PRNewswire PRNewswire • 12-22-2022
By GuruFocusNews GuruFocusNews • 05-31-2022
By Business Wire Business Wire • 02-14-2023
By Tiesvg Tiesvg • 12-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.